Published in J Cancer on July 11, 2013
Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection. PLoS One (2016) 0.78
Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of iran. Jundishapur J Microbiol (2015) 0.75
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Chronic hepatitis B. Hepatology (2001) 5.90
HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (1991) 5.34
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology (2001) 4.28
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol (2011) 3.88
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med (1999) 3.08
Management of HCC. J Hepatol (2012) 3.03
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology (2013) 2.66
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest (1994) 2.10
Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Intern Med (2011) 2.09
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med (2007) 1.97
A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg (2009) 1.97
Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut (2000) 1.82
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res (2005) 1.64
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer (1999) 1.48
Clinical impact of occult HBV infections. J Clin Virol (2005) 1.46
Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur J Cancer Prev (2013) 1.43
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol (1999) 1.40
Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect (2009) 1.39
Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int (2011) 1.39
Occult HBV infection. Semin Immunopathol (2012) 1.37
Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology (1998) 1.36
Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol (2002) 1.34
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer (2006) 1.33
Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30
Treatment options in hepatocellular carcinoma today. Scand J Surg (2011) 1.23
Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol (1995) 1.20
Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology (2011) 1.20
Clinical aspects of hepatitis B virus infection. Lancet (1993) 1.20
Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer (2010) 1.15
Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol (2007) 1.09
Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology (2009) 1.06
Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat (2009) 1.04
Occult hepatitis B among chronic liver disease patients. Saudi Med J (2005) 1.03
Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol (2008) 1.03
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol (2005) 1.01
Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol (2008) 0.96
Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology (2008) 0.95
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 0.94
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. J Med Virol (2010) 0.94
Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis (2011) 0.93
Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int (2005) 0.92
[An analysis of hepatitis B virus infection rate in 405 cases of non-Hodgkin lymphoma]. Zhonghua Xue Ye Xue Za Zhi (2011) 0.92
Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis (2000) 0.91
A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol (2007) 0.91
Current information on the immunologic status of occult hepatitis B infection. Transfusion (2012) 0.91
Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol (2012) 0.91
Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol (2012) 0.90
Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res (2008) 0.90
HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol (2003) 0.89
Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J (2011) 0.86
Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon (2012) 0.86
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85
Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma. Ann Surg (2011) 0.84
Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol (2004) 0.84
Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat (2013) 0.84
Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis (2012) 0.83
Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study. Hepatol Res (2013) 0.83
Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma. Anticancer Res (2013) 0.79
Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma. Oncol Rep (2013) 0.76
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol (2003) 2.87
Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology (2004) 2.66
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med (2007) 1.97
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One (2011) 1.39
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology (2011) 1.32
Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol (2006) 1.11
Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology (2008) 1.10
Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology (2007) 1.10
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol (2010) 1.08
Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One (2012) 1.08
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int (2014) 1.05
Two cases of acute necrotizing pancreatitis complicating after transcatheter arterial embolization for hepatocellular carcinoma. J Gastroenterol (2005) 1.01
Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol (2011) 0.98
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol (2014) 0.98
Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol (2011) 0.97
Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol (2008) 0.97
Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer (2013) 0.97
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol (2014) 0.93
Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia (2013) 0.93
Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol (2013) 0.93
Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology (2006) 0.92
Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion (2011) 0.92
A case of allergic contact dermatitis from propylene glycol in an ultrasonic gel, sensitized at a leakage skin injury due to transcatheter arterial chemoembolization for hepatocellular carcinoma. Int J Dermatol (2005) 0.91
Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol (2012) 0.91
Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol (2008) 0.91
Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol (2012) 0.90
Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res (2013) 0.90
Prominent hypereosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer. Intern Med (2014) 0.90
Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology (2014) 0.89
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther (2014) 0.89
Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis (2013) 0.89
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) (2012) 0.89
A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol (2010) 0.89
The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes (2012) 0.88
Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol (2012) 0.88
Visualization of blood drainage area from hypervascular hepatocellular carcinoma on ultrasonographic images during hepatic arteriogram: Comparison with depiction of drainage area on contrast-enhanced ultrasound. Hepatol Res (2012) 0.87
Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. Eur J Gastroenterol Hepatol (2013) 0.87
Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med (2013) 0.86
Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol (2013) 0.86
Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol (2006) 0.85
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther (2014) 0.85
A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology (2008) 0.85
Clinical characteristics of collagenous colitis with linear ulcerations. Dig Endosc (2013) 0.85
Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res (2013) 0.85
Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis (2012) 0.85
Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma. J Gastrointestin Liver Dis (2013) 0.84
Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J Gastroenterol (2003) 0.84
The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol (2013) 0.84
Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res (2007) 0.83
Dense-type crypt opening seen on magnifying endoscopy with narrow-band imaging is a feature of gastric adenoma. Dig Endosc (2013) 0.83
Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol (2012) 0.83
Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res (2014) 0.82
Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci (2012) 0.82
Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma. Anticancer Res (2013) 0.82
Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett (2013) 0.81
Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res (2015) 0.81
The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma. Gastroenterol Res Pract (2013) 0.81
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol (2014) 0.80
Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. Oncology (2014) 0.80
Risk factors associated with recurrent hemorrhage after the initial improvement of colonic diverticular bleeding. Acta Gastroenterol Belg (2013) 0.80
A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Rep Oncol (2010) 0.79
Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. J Gastroenterol (2013) 0.79
Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma. Anticancer Res (2013) 0.79
Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci (2006) 0.79
Double primary cancers: intrahepatic cholangiocarcinoma with myocardial metastases and lung squamous cell carcinoma. Intern Med (2012) 0.78
Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma. Oncol Rep (2013) 0.78
Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep (2012) 0.78
Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatol Res (2013) 0.78
Gastric xanthelasma may be a warning sign for the presence of early gastric cancer. J Gastroenterol Hepatol (2014) 0.78
Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol (2002) 0.77
[A case of α-fetoprotein-producing hepatoid adenocarcinoma of the stomach with spontaneous rupture of multiple liver metastases]. Nihon Shokakibyo Gakkai Zasshi (2013) 0.77
Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer (2015) 0.77
Endoscopic ultrasonography-guided transgastric drainage of infectious biloma following radiofrequency ablation for hepatocellular carcinoma. Dig Endosc (2012) 0.77
A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol Res (2005) 0.77
Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma. Anticancer Res (2012) 0.76
Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma. Oncol Rep (2013) 0.76
Clinical significance of the genotype and core promoter/pre-core mutations in hepatitis B virus carriers. Intervirology (2006) 0.76
Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med (2012) 0.76
Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol (2012) 0.75
A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) (2016) 0.75
Biliary peritonitis after radiofrequency ablation diagnosed by gadoxetic acid-enhanced MR imaging. Korean J Radiol (2013) 0.75
A case of Zollinger-Ellison syndrome diagnosed by duodenal ulcer perforation into the gallbladder. Gastrointest Endosc (2013) 0.75
[A case of diffuse cystic malformation in which submucosal tumor-like advanced gastric cancer was identified during 10-year follow-up]. Nihon Shokakibyo Gakkai Zasshi (2012) 0.75
Idiopathic portal hypertension with multiple hepatic hyperplastic nodules supplied by portal vein. Ann Hepatol (2012) 0.75
[Case of moderately differentiated hepatocellular carcinoma with gastric metastasis]. Nihon Shokakibyo Gakkai Zasshi (2008) 0.75
[Tuberculous peritonitis diagnosed by laparoscope, differentiated from Fitz-Hugh-Curtis syndrome]. Nihon Naika Gakkai Zasshi (2007) 0.75
Cap-polyposis-like gastropathy with hypoproteinemia treated with H. pylori eradication. Intern Med (2012) 0.75
[Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers]. Gan To Kagaku Ryoho (2009) 0.75
[An autopsy case of allergic granulomatous angitis (Churg Strauss syndrome) with heart failure and HSV infection following perforation of the small intestine]. Nihon Shokakibyo Gakkai Zasshi (2002) 0.75
[A case of infected liver cyst caused by salmonella paratyphi A]. Nihon Shokakibyo Gakkai Zasshi (2003) 0.75
[A case of primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype: comparison of hemodynamics and histopathology]. Nihon Shokakibyo Gakkai Zasshi (2010) 0.75